A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) With 0.5gm Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab.
Phase of Trial: Phase I/II
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2011 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 04 May 2010 Planned end date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 29 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.